Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Rezolute Inc (NQ: RZLT ) 4.350 -0.020 (-0.46%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Rezolute Inc < Previous 1 2 Next > Rezolute to Participate in Upcoming Investor Conferences August 27, 2024 From Rezolute, Inc. Via GlobeNewswire Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism August 05, 2024 From Rezolute, Inc. Via GlobeNewswire Rezolute to Participate in the BTIG Virtual Biotechnology Conference July 31, 2024 From Rezolute, Inc. Via GlobeNewswire Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement June 27, 2024 Additional $6.7M in funding resulting in approximately $67M in gross proceeds From Rezolute, Inc. Via GlobeNewswire Rezolute Inc. (NASDAQ: RZLT) Climbs to New 52-Week High April 15, 2024 Via Investor Brand Network Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds June 24, 2024 From Rezolute, Inc. Via GlobeNewswire Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants June 13, 2024 From Rezolute, Inc. Via GlobeNewswire Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants June 13, 2024 From Rezolute, Inc. Via GlobeNewswire Rezolute to Participate in the Jefferies Global Healthcare Conference May 30, 2024 From Rezolute, Inc. Via GlobeNewswire Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) May 21, 2024 From Rezolute, Inc. Via GlobeNewswire Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update May 15, 2024 From Rezolute, Inc. Via GlobeNewswire Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting April 23, 2024 From Rezolute, Inc. Via GlobeNewswire 3 Stocks Insiders Are Buying That Analysts Love March 26, 2024 Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits. Via MarketBeat Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) March 06, 2024 Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) From Rezolute, Inc. Via GlobeNewswire Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update February 13, 2024 From Rezolute, Inc. Via GlobeNewswire Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer January 24, 2024 From Rezolute, Inc. Via GlobeNewswire Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism January 23, 2024 From Rezolute, Inc. Via GlobeNewswire Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”) December 13, 2023 Plans to report topline data mid-second quarter 2024 From Rezolute, Inc. Via GlobeNewswire Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS" November 24, 2023 Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday... Via Newsfile Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day November 17, 2023 From Rezolute, Inc. Via GlobeNewswire Rezolute Reports First Quarter Fiscal 2024 Results November 13, 2023 From Rezolute, Inc. Via GlobeNewswire Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism October 17, 2023 PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism From Rezolute, Inc. Via GlobeNewswire Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism October 11, 2023 From Rezolute, Inc. Via GlobeNewswire Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress September 14, 2023 Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023 From Rezolute, Inc. Via GlobeNewswire Rezolute to Participate in Upcoming Investor Conferences in September September 06, 2023 From Rezolute, Inc. Via GlobeNewswire Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism June 27, 2023 From Rezolute, Inc. Via GlobeNewswire Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease June 01, 2023 Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare... Via Newsfile Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress May 11, 2023 The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023 From Rezolute, Inc. Via GlobeNewswire Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema March 23, 2023 RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye From Rezolute, Inc. Via GlobeNewswire Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert March 08, 2023 Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT From Rezolute, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.